Showing posts with label As. Show all posts
Showing posts with label As. Show all posts

Friday, July 21, 2017

Support For Marijuana As Pain Killer How To Keep It Real


Today's headline-grabbing post from fool.com (see link below) may well attract yet more readers to the medical marijuana fold but we do need to ask precisely what is meant by every step forward regarding medicinal marijuana. We should know by now that just because on a certain day, something is seen as good and beneficial, it doesn't mean to say that the next day, things will be the same. That certainly applies to marijuana and the whole issue may well be drastically influenced by coming elections in the US. So having achieved so much progress towards recognising the medical qualities of marijuana, especially as an analgesic, how do we maintain that progress in a world where the media can change your mind every minute? The answer lies in maintaining factual reporting - no hints, suggestions or suppositions but cold hard indisputable facts. Only then can indisputable things about marijuana be said. It is not surprising that the first genuine breakthrough in pain treatment in decennia has been so widely welcomed but we must always be careful that the facts remain paramount and are not exaggerated by 'wishful thinking' because that's exactly what opponents of medical marijuana are waiting for.

Public Support for Marijuana Just Hit an All-Time High
 
Sean Williams (TMFUltraLong) Oct 29, 2016 at 9:12AM

Though marijuana is no longer a taboo topic, and industry expansion appears likely, investors should remain cautious.

The sun is shining on the marijuana industry.

Put plainly, you'd struggle to find an industry that's growing as consistently fast as marijuana. While it's not uncommon to find an industry that has double-digit growth potential for a few years, investment bank Cowen & Co.'s estimates suggest the legal cannabis market could expand by nearly 24% per year through 2026 to about $50 billion. Those are numbers that are hard for businesses and investors to overlook.
Public support for pot soars

It's what's going on behind the scenes that's truly remarkable. In a relatively short period of two decades marijuana has been transformed from one of the most taboo topics to a substance that's now recognized as medically legal in half of all U.S. states. It's also legal to purchase certain amounts of recreational marijuana in four states -- Colorado, Washington, Oregon, and Alaska -- along with Washington, D.C., for adults ages 21 and up.

The real impetus for change in the cannabis industry has been the rapidly shifting, and improving, public opinion toward the drug. According to the many polls Gallup has conducted over a nearly five-decade period, it's only since the mid-1990s that the public's opinion of marijuana has shifted. In 1995, just 25% of Gallup's respondents wanted to see pot legalized nationally. By 2005, that figure had risen to 36%, and by 2011 it touched 50% for the first time. With the national pollster releasing its 2016 marijuana poll earlier this month one thing is clear: marijuana is no longer taboo.


Image source: Cannabis Culture via Flickr.


According to Gallup, support for legalizing marijuana nationally has now hit 60%, an all-time high (no pun intended). Growing public support could put pressure on the legislatures of the remaining states that haven't legalized marijuana -- especially those that don't have the initiative and referendum process -- to reconsider their position on medical cannabis. As a reminder, support for legalizing only medical cannabis is even higher, with a 2015 CBS News poll putting favorability for such a measure at 84%.

A recently released marijuana poll from the Pew Research Center would appear to concur with Gallup's findings. Nearly three weeks ago Pew Research pegged support for legalizing marijuana at 57%, an all-time high, with just 37% preferring it remain illegal. Comparatively, 60% of respondents wanted it to remain illegal just one decade prior.

Even with the U.S. Drug Enforcement Agency rejecting two petitions to reschedule marijuana in August, the industry looks as if it could continue to grow on the heels of strong support from the American public.
One thing for opportunistic investors to keep in mind

Growing support for marijuana might have opportunistic investors thinking that buying into the cannabis industry is a smart move. However, certain aspects of the industry continue to make it anything but investor-friendly.

To begin with, there aren't many investable marijuana stocks. With the exception of GW Pharmaceuticals, which has discovered more than five dozen cannabinoids and is attempting to use those cannabinoids to effect positive biologic changes in the treatment of epilepsy, cancer, and type 2 diabetes, to name a few ailments, there aren't any other pot stocks trading on reputable stock exchanges. Although we're witnessing improved reporting standards for over-the-counter stock platforms, those standards still aren't the same as if they were listed on the NYSE or Nasdaq, which makes finding accurate financial information somewhat spotty. Not to mention, nearly all marijuana companies are currently losing money.

The cannabis industry also faces a number of disadvantages that are liable to turn investors off. For example, pot companies are having a very difficult time accessing basic financial services from banks and credit unions. Though many states that have legalized medical and/or recreational marijuana have provided a workaround for banks and credit unions to legally provide a checking account or line of credit to pot businesses, the fact that banks are insured by the federal government could theoretically expose them to prosecution in the future. Remember, cannabis remains illegal at the federal level. This means most banks (about 97%) have remained on the sidelines, which is forcing cannabis businesses to deal solely in cash -- and cash creates a major security concern.

Additionally, marijuana companies are contending with a major disadvantage come tax time. The Internal Revenue Service disallows businesses that sell illicit substances, such as marijuana, from taking normal business deductions. It essentially means pot businesses are paying tax on their gross profits instead of net profits; or in other words, dramatically overpaying on their taxes compared to "normal businesses." Having to hand back a lot of would-be profit to the federal government isn't exactly ideal from a business perspective.

Thus, while the marijuana industry looks poised for continued expansion at the state level based on improving public support, the fundamental factors that are behind the scenes still indicate that investors would be better off sticking on the sidelines.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

http://www.fool.com/investing/2016/10/29/public-support-for-marijuana-just-hit-an-all-time.aspx

Friday, June 9, 2017

Snail Saliva As Effective as Morphine for Neuropathy


Following on from recent posts looking at unusual potential sources of pain relief, today's post from emaxhealth.com (see link below) examines the promising properties of a sort of sea snail saliva. It could possible rival morphine in its pain-killing properties and anything that could be a non-addictive substitute for morphine must be welcome in the neuropathy community. Don't expect it to appear soon on the list of approved drugs. They've managed to develop a synthetic version but that has to be injected into the spine and nobody's waiting for that sort of treatment. Still a long way to go then but it's great that people are seriously searching the natural world for alternatives to morphine.

Snail Saliva As Effective as Morphine?
By Deborah Mitchell on July 28, 2010

To treat severe pain, a sea snail may hold an answer. Scientists have developed a new medication first isolated from sea snail saliva that may be as effective as morphine.

Sea snails may not move fast, but what they lack in speed, they more than make up for in chemicals. These animals have the ability to inject a mixture of toxins called conotoxins into their targeted prey using their needle-like teeth.

These conotoxins consist of peptides that can relieve severe neuropathic pain as effectively as morphine, but it does not lead to addiction. Attempts to transform these conotoxins into a drug that could be used as a pain reliever has been challenging. Thus far a synthetic version has been developed, but it must be injected directly into the spinal cord using an implanted pump.

Now, a team of scientists in Australia have developed a conotoxin that can be taken orally. In tests with rats, the new drug proved to be as effective a pain killer as gabapentin, which is the most popular drug to treat neuropathic pain. Compared with the dose of gabapentin needed to treat pain, however, the conotoxin-based peptide (named Prialt) is less than 1 percent.

The research team, led by David J. Craik of the Institute for Molecular Bioscience at the University of Queensland, noted that peptides have generally been regarded to be poor pain killers because they are not stable and mostly not available in oral form. One exception has been the immunosuppressant cyclosporine.

Could a drug based on sea snail saliva be next? Jon-Paul Bignham, a professor of molecular biosciences and bioengineering at the University of Hawaii, Manoa, pointed out that an oral drug that has the pain killer abilities of Prialt “would absolutely revolutionize how we manage chronic and terminal pain.” Move over, morphine.

SOURCE:
Chemical & Engineering News 2010 July 26; 88(30): 39-40






http://www.emaxhealth.com/1275/snail-saliva-effective-morphine